@AGatlin_IBD Allison Gatlin
Allison Gatlin posts on X about $nvo, company, $lly, $sny the most. They currently have [---] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.
Engagements: [--] #
- [--] Week [-----] +396%
- [--] Month [------] +180%
- [--] Months [------] +26%
- [--] Year [------] +47%
Mentions: [--] #
- [--] Week [--] -4.40%
- [--] Month [--] +66%
- [--] Months [---] +45%
- [--] Year [---] +6,650%
Followers: [---] #
- [--] Week [---] +1.10%
- [--] Month [---] +1.30%
- [--] Months [---] +31%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 66% finance 22% cryptocurrencies 9% countries 2% currencies 2% travel destinations 1%
Social topic influence $nvo 12%, company 11%, $lly #114, $sny #38, eli lilly #152, in the 5%, beat 5%, sanofi #62, $rhhby 5%, stocks 5%
Top accounts mentioned or mentioned by @thehill @llcooljosh22 @ibdagatlin
Top assets mentioned Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Synthetify (SNY) Sanofi (SNY) Medpace Holdings, Inc. Common Stock (MEDP) Basilisk (BSX) Metsera, Inc. (MTSR) GSK plc (GSK) Ventyx Biosciences, Inc. (VTYX) Regeneron Pharmaceuticals Inc (REGN) Amgen, Inc. (AMGN) Boston Scientific Corporation (BSX) Intuitive Surgical, Inc. (ISRG) Pfizer, Inc. (PFE) Merck & Co., Inc. (MRK) Johnson & Johnson (JNJ) Sarepta Therapeutics, Inc. (SRPT) AstraZeneca PLC (AZN) BridgeBio Pharma, Inc. Common Stock (BBIO) AbbVie Inc (ABBV) Alkermes Inc. plc (ALKS) Viking Therapeutics, Inc (VKTX) Hims & Hers Health, Inc. (HIMS) CRISPR Therapeutics AG (CRSP) TG Therapeutics, Inc. (TGTX) Travere Therapeutics, Inc. Common Stock (TVTX) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Bristol-Myers Squibb Co (BMY) Novartis AG (NVS) BEAM (BEAM) IDEXX Laboratories, Inc. (IDXX) BioAge Labs, Inc. (BIOA) InMode Ltd. Ordinary Shares (INMD) Incyte Corporation (INCY) Evommune, Inc. (EVMN) GH Research PLC (GHRS) Abbott Laboratories (ABT) Arcblock (ABT) ImmunityBio, Inc. Common Stock (IBRX) Zoetis Inc (ZTS) Icon Plc (ICLR) Hologic, Inc. (HOLX) Danaher Corporation (DHR) uniQure N.V. (QURE) Cogent Biosciences, Inc. Common Stock (COGT) Ligand Pharmaceuticals Inc. (LGND)
Top Social Posts
Top posts by engagements in the last [--] hours
"$BIOA rocketed after the company reported promising results for its NLRP3 blocker a potential cardiovascular treatment and rival to $LLY takeover play $VTYX. https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/ https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/"
X Link 2026-01-12T18:33Z [---] followers, [---] engagements
"$SRPT surged on promising three-year results for Elevidys. But analysts are split on whether it will help uptake for the embattled gene therapy. $SLDB $RGNX https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/ https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/"
X Link 2026-01-26T21:19Z [---] followers, [---] engagements
"$INMD got a boost after an Israeli news site reported the medical aesthetics company is in advanced talks to be acquired for $1.1 billion. https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/ https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/"
X Link 2026-01-26T21:20Z [---] followers, [---] engagements
"An analyst with RBC says $REGN could soon become acquisitive. The press release reads "more direct" on the potential for business development than it has in the past. $SNY $BAYRY https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/ https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/"
X Link 2026-01-30T17:34Z [---] followers, [----] engagements
"$LLY issued "assertive" guidance Wednesday well above expectations. Analysts say this helps following $NVO's downbeat outlook on Tuesday. https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/ https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/"
X Link 2026-02-04T17:07Z [---] followers, [---] engagements
"$NVO continued its two-day plunge Wednesday after the company said it expects sales and operating profit to fall this year. Here's what CFO Karsten Knudsen had to say about the outlook and how oral Wegovy could fit in. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/"
X Link 2026-02-04T17:16Z [---] followers, [---] engagements
"The biotech industry in China is taking off. My A1 feature this week examines why Big Pharma is taking China seriously -- as a partner and a rival. https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/ https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/"
X Link 2026-02-06T17:49Z [---] followers, [---] engagements
"It's been a busy earnings morning with $INCY down on its Opzelura outlook despite a solid Q4 report and $AZN up on its beat and outlook. $MEDP is under pressure though on its book-to-bill ratio. https://www.investors.com/news/technology/medpace-stock-medpace-earnings-q4-2025/ https://www.investors.com/news/technology/astrazeneca-stock-astrazeneca-earnings-q4-2025/ https://www.investors.com/news/technology/incyte-stock-incyte-earnings-q4-2025/ https://www.investors.com/news/technology/medpace-stock-medpace-earnings-q4-2025/"
X Link 2026-02-10T18:13Z [---] followers, [---] engagements
"Outside of earnings $NKTR and $EVMN are up by double digits on promising test results in eczema treatment. Analysts compared both to $REGN and $SNY's blockbuster Dupixent. https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/ https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/"
X Link 2026-02-10T18:14Z [---] followers, [---] engagements
"An analyst says $BBIO could change the standard of care in achondroplasia causes disproportionate short-limb stature. The company hit its bull case for the Phase [--] study. https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/ https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/"
X Link 2026-02-12T20:36Z [---] followers, [----] engagements
"$SNY unexpectedly ousted CEO Paul Hudson earlier today. He will be succeeded by Merck KGaA's Belen Garijo. https://www.investors.com/news/technology/sanofi-stock-paul-hudson-belen-garijo-ceo-transition/ https://www.investors.com/news/technology/sanofi-stock-paul-hudson-belen-garijo-ceo-transition/"
X Link 2026-02-12T20:38Z [---] followers, [---] engagements
"$GHRS rocketed to its highest point since July after the FDA lifted the clinical hold preventing it from testing its psychedelics-tied depression drug. https://www.investors.com/news/technology/biotech-stock-gh-research-depression-treatment-psychedelics/ https://www.investors.com/news/technology/biotech-stock-gh-research-depression-treatment-psychedelics/"
X Link 2026-01-05T15:41Z [---] followers, [---] engagements
"$ABT is under pressure down more than 8% at the moment on a disappointing fourth-quarter report and EPS outlook for the first quarter. Read on: https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q4-2025/ https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q4-2025/"
X Link 2026-01-22T17:29Z [---] followers, [---] engagements
"$RHHBY rose into a profit-taking zone Thursday after falling Wednesday. The company says it plans to file for approval of four new obesity drugs in [----]. $LLY $NVO https://www.investors.com/news/technology/roche-stock-roche-earnings-q4-2025/ https://www.investors.com/news/technology/roche-stock-roche-earnings-q4-2025/"
X Link 2026-01-29T21:23Z [---] followers, [---] engagements
"ICYMI: $AMGN beat fourth-quarter forecasts and shares surged on surprisingly upbeat [----] guidance given biosimilar competition facing Prolia and Xgeva. https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q4-2025/ https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q4-2025/"
X Link 2026-02-04T17:04Z [---] followers, [---] engagements
"$ABBV and $BSX both slumped Wednesday. AbbVie beat fourth-quarter expectations but the beat was largely thanks to Humira while Boston Scientific's electrophysiology sales came in light. AbbVie: Boston Scientific: https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q4-2025/ https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2025/ https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q4-2025/ https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2025/"
X Link 2026-02-04T17:09Z [---] followers, [---] engagements
"@LLCoolJosh22 Thank you Josh I havent examined $IBRX. Dollar stocks are tricky. We tend to focus on higher-value stocks"
X Link 2026-02-07T21:21Z [---] followers, [---] engagements
"BREAKING: FDA refuses to review $MRNA's flu vaccine. https://www.investors.com/news/technology/moderna-stock-fda-cber-mrna-based-flu-shot/ https://www.investors.com/news/technology/moderna-stock-fda-cber-mrna-based-flu-shot/"
X Link 2026-02-10T23:18Z [---] followers, [---] engagements
"$ZTS is under pressure after beating fourth-quarter forecasts but on unexpected strength from its smaller livestock division. https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q4-2025/ https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q4-2025/"
X Link 2026-02-12T20:37Z [---] followers, [---] engagements
"$ICLR plummeted after pulling its [----] EPS guidance amid an investigation into accounting practices. https://www.investors.com/news/technology/icon-stock-accounting-practices-investigation/ https://www.investors.com/news/technology/icon-stock-accounting-practices-investigation/"
X Link 2026-02-12T20:39Z [---] followers, [---] engagements
"$HOLX agreed to an $18.3 billion take-private deal. Shares rose last week on rumors Blackstone and TPG bid $16 billion to buy it. https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/ https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/"
X Link 2025-10-21T17:20Z [---] followers, [---] engagements
"$DHR surged topping its buy zone on a strong earnings report backed by its bioprocessing division. https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/ https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/"
X Link 2025-10-21T17:20Z [---] followers, [---] engagements
"ICYMI: $ISRG smashed earnings expectations late Tuesday. Shares are up by double digits today helped by the hiked procedure growth guidance for [----]. https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/"
X Link 2025-10-22T19:28Z [---] followers, [---] engagements
"$BSX jumped after one of its key segments posted 63% sales growth. https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/ https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/"
X Link 2025-10-22T19:33Z [---] followers, [---] engagements
"Here's what confused the Street about $ALKS' buyout of $AVDL says one analyst. https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/ https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/"
X Link 2025-10-22T19:33Z [---] followers, [---] engagements
"On the earnings front $MEDP had a strong showing with a massive 1.20x book-to-bill ratio that impressed investors and analysts. The company beat its own forecast for 1.15x. https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/ https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/"
X Link 2025-10-23T20:26Z [---] followers, [---] engagements
"$VKTX stock also put up a strong showing after the company said it expects to finish enrolling patients in two Phase [--] obesity treatment studies later this year and early next. https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/ https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/"
X Link 2025-10-23T20:27Z [---] followers, [---] engagements
"$MTSR says $PFE's claims are "nonsense." The latter is suing Metsera and $NVO over their proposed $6.5 billion deal. Novo swooped in last week widely Pfizer's $4.9 billion deal to buy Metsera an obesity-focused biotech. https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/ https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/"
X Link 2025-11-03T18:19Z [---] followers, [---] engagements
"$QURE is under pressure down roughly 50% after the FDA issued unexpected feedback on its gene therapy for Huntington's disease. The news comes less than six weeks after UniQure stock skyrocketed almost 250% on positive test results. https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/ https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/"
X Link 2025-11-03T18:21Z [---] followers, [---] engagements
"I got [--] minutes this morning to chat with $NVO's CFO Karsten Munk Knudsen about $MTSR $HIMS $LLY and of course the company's third guidance cut this year. Here's why he says Novo Nordisk's "hyper growth" has stalled. https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/"
X Link 2025-11-05T21:25Z [---] followers, [---] engagements
"It's been a wild week for the weight-loss drugs segment with $LLY and $NVO inking MFN deals and Novo duking it out with $PFE to buy $MTSR. Earlier this year obesity stocks were in a rut. Now Some of them are telling a different story. https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/ https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/"
X Link 2025-11-07T22:55Z [---] followers, [---] engagements
"ICYMI: $MRK and $CRSP unveiled positive results for cholesterol treatments. Merck's is a daily pill while Crispr's would be a one-time gene-editing treatment. https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/ https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/"
X Link 2025-11-10T18:34Z [---] followers, [---] engagements
"$ANAB reversed a recent 70% run after its ulcerative colitis drug failed in midstage testing. One analyst pegged it as having only a 15% chance of succeeding. https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/ https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/"
X Link 2025-11-10T18:35Z [---] followers, [---] engagements
"Meanwhile the battle with $RHHBY and $TGTX continues in multiple sclerosis. TG took the most recent hit. https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/ https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/"
X Link 2025-11-10T18:35Z [---] followers, [---] engagements
"Also ICYMI: The $PFE and $NVO battle to acquire $MTSR ended on Friday. Here's how it went down: https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/ https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/"
X Link 2025-11-10T18:36Z [---] followers, [---] engagements
"$COGT is up by triple digits on a first in [--] years development in treating second-line GIST. https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/ https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/"
X Link 2025-11-10T19:33Z [---] followers, [---] engagements
"On the M&A and cancer front $JNJ is buying privately held Halda Therapeutics. It's working on oral treatments that could treat a myriad of cancers. https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/ https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/"
X Link 2025-11-17T22:42Z [---] followers, [---] engagements
"$NVO lowered the price of its GLP-1 drugs Ozempic and Wegovy on its NovoCare DTC website. The price is lower than what $LLY charges for its rival drugs Mounjaro and Zepbound. https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/ https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/"
X Link 2025-11-17T22:42Z [---] followers, [---] engagements
"My I&T feature this week focuses on $LGND the royalty-focused biotech backer behind $TVTX's Filspari and $MRK's Ohtuvayre. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/ https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/"
X Link 2025-11-18T18:23Z [---] followers, [---] engagements
"$MRK said Tuesday sotatercept (branded Winrevair) showed promise in patients with a form of pulmonary hypertension. But the company doesn't seem to be filing with the FDA based on these results. https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/ https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/"
X Link 2025-11-18T18:24Z [---] followers, [---] engagements
"$MDT broke out of a flat base helped by massive growth for its pulsed field ablation technology. It rivals $BSX in that segment. https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/"
X Link 2025-11-18T18:25Z [---] followers, [---] engagements
"Today's IBD #SOTD takes a look at $MEDP which shot higher on its massive book-to-bill beat in the third quarter. But analysts wonder if Medpace is worth its sky-high valuation relative to other CRO stocks. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/"
X Link 2025-11-18T19:32Z [---] followers, [---] engagements
"While quieter than the $NVO and $PFE dustup over Metsera $ALKS and Lundbeck are continuing to trade bids over $AVDL. Today Alkermes has the "superior proposal." https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/ https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/"
X Link 2025-11-19T18:41Z [---] followers, [---] engagements
"$VKTX slumped though the company said it over-enrolled a study of its obesity treatment VK2735. https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/ https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/"
X Link 2025-11-19T18:42Z [---] followers, [---] engagements
"$AGIO plummeted while $FULC surged after Agios said mitapivat missed its goal in a Phase [--] study of patients with sickle cell disease. https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/ https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/"
X Link 2025-11-19T18:43Z [---] followers, [---] engagements
"My A1 story this week takes a look at the ADC space or what we've been calling "smart bombs" for cancer in the newsroom. It seems all the big oncology names are in this space including $AZN $GSK $ABBV $RHHBY and others. https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/ https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/"
X Link 2025-11-21T16:57Z [---] followers, [---] engagements
"This week's New America feature takes a look at $TVTX which is nearing potential approval of a second condition for its drug Filspari. Filspari treats IgAN but could win the OK to treat another kidney disease FSGS in January. https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/ https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/"
X Link 2025-11-26T17:47Z [---] followers, [---] engagements
"In pharma news CMS revealed the negotiated prices for a basket of [--] drugs beginning in [----]. $NVO and $TEVA shares rose while other stocks were more muted. Unrelated $SNY is under pressure after French authorities raided its Paris HQ. https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/ https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/"
X Link 2025-11-26T17:49Z [---] followers, [---] engagements
"Sanofi confirmed the tax fraud investigation: https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/ https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/"
X Link 2025-11-26T17:49Z [---] followers, [--] engagements
"Our I&T feature is out early this week and takes a look at $BBIO featuring an interview with CEO Neil Kumar. BridgeBio stock has run up by triple digits this year amid several Phase [--] readouts with another in the works. https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/ https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/"
X Link 2025-12-02T17:18Z [---] followers, [---] engagements
"$CAPR surged as much as 535% today -- shares are currently up about 340% -- on promising test results for its cell therapy approach to Duchenne muscular dystrophy. This follows a CRL earlier in the fall. https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/ https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/"
X Link 2025-12-03T19:13Z [---] followers, [---] engagements
"$RCUS tumbled reversing a winning streak over the past eight months after its $GILD-partnered anti-TIGIT drug failed in upper gastrointestinal cancers. https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/ https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/"
X Link 2025-12-12T18:10Z [---] followers, [---] engagements
"@thehill has a slightly wider camera. I can also see $AMGN and $BMY"
X Link 2025-12-19T19:07Z [---] followers, [--] engagements
"@thehill The full list includes $SNY $NVS $RHHBY's Genentech Boehringer Ingelheim $GILD $BMY $GSK $MRK and $AMGN. Trump says that [--] out of [--] of the biggest pharma companies. He says the other [--] have also signed deals including $JNJ"
X Link 2025-12-19T19:33Z [---] followers, [---] engagements
"$ARWR followed in the footsteps of $WVE silencing the gene responsible for activin E to improve fat loss. Shares are up by double digits. But one analyst says Wave could have the edge. https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/ https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/"
X Link 2026-01-06T16:27Z [---] followers, [----] engagements
"$LLY confirmed its $1.2 billion plan to acquire $VTYX late Wednesday. https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/ https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/"
X Link 2026-01-07T23:16Z [---] followers, [---] engagements
"Here's today's #SOTD which focused on $LLY's rally following the initial rumors of the $VTYX deal. https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/ https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/"
X Link 2026-01-07T23:16Z [---] followers, [---] engagements
"#Biotech stocks made a comeback in the latter half of [----] soaring more than 82% from a low point in April amid a flurry of M&A deals and enthusiasm for strong clinical data. Here's what experts are watching for this year. https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/ https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/"
X Link 2026-01-08T16:51Z [---] followers, [---] engagements
"$TVTX was hammered after the company said it just wrapped answering FDA questions ahead of its Jan. [--] PDUFA for Filspari in FSGS. The late FDA request and response could indicate a delay for Filspari. https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/ https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/"
X Link 2026-01-13T18:50Z [---] followers, [---] engagements
"Today's #SOTD takes a look at $MEDP as shares flirt with an early entry. The biotech funding environment looks strong which could benefits CROs. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/"
X Link 2026-01-13T21:22Z [---] followers, [---] engagements
"$NVO is up 9% at the moment benefitting from a strong first week of Wegovy pill prescriptions. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/"
X Link 2026-01-16T19:43Z [---] followers, [---] engagements
"Today #SOTD take a look at $CAH which bounded off its 21-day line on continued momentum for the biopharma industry. https://www.investors.com/research/ibd-stock-of-the-day/cardinal-health-2026-guidance-hike/ https://www.investors.com/research/ibd-stock-of-the-day/cardinal-health-2026-guidance-hike/"
X Link 2026-01-26T21:21Z [---] followers, [---] engagements
"$RAPP shares doubled and then some on Monday after the company said its daily pill reduced focal onset seizures by nearly 78% in an eight-week study. https://www.investors.com/news/technology/rapport-therapeutics-focal-onset-seizures-treatment/ https://www.investors.com/news/technology/rapport-therapeutics-focal-onset-seizures-treatment/"
X Link 2025-09-08T20:13Z [---] followers, [---] engagements
"$TEVA on the other hand skyrocketed after maintaining its Austedo guidance for [----] and beyond despite a looming price cut under the IRA. CEO Richard Francis says the company's thoughtful approach to guidance was on display today. https://www.investors.com/news/technology/teva-stock-teva-pharmaceutical-earnings-q3-2025/ https://www.investors.com/news/technology/teva-stock-teva-pharmaceutical-earnings-q3-2025/"
X Link 2025-11-05T21:26Z [---] followers, [---] engagements
"The most M&A news of #JPM2026 took place on the last day. $BSX is buying $PEN while $OCUL briefly launched on a report $SNY could buy it. https://www.investors.com/news/technology/boston-scientific-will-buy-penumbra-14-5-billion-medtech-deal/ https://www.investors.com/news/technology/ocular-therapeutix-sanofi-takeover-rumor/ https://www.investors.com/news/technology/boston-scientific-will-buy-penumbra-14-5-billion-medtech-deal/ https://www.investors.com/news/technology/ocular-therapeutix-sanofi-takeover-rumor/"
X Link 2026-01-15T21:22Z [---] followers, [---] engagements
"The gene-editing space got a boost earlier today after $LLY announced its plan to buy $VERV for up to $1.3 billion. $NTLA $EDIT $CRSP $BEAM https://www.investors.com/news/technology/verve-therapeutics-stock-eli-lilly-buyout-gene-editing-stocks/ https://www.investors.com/news/technology/verve-therapeutics-stock-eli-lilly-buyout-gene-editing-stocks/"
X Link 2025-06-17T19:08Z [---] followers, [---] engagements
"Starting over is hard. Yet here I am. A week ago my professional X/Twitter account @IBD_AGatlin was hacked. Unfortunately it looks like I have to let that one go. If you followed me over there and enjoyed my posts please follow me here"
X Link 2025-02-06T23:04Z [---] followers, [----] engagements
"$HRMY took a hit after the FDA rejected Wakix as a treatment for idiopathic hypersomnia. The drug missed its primary endpoint in Phase [--] testing but the company was hoping the FDA would look at the totality of its data. https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/ https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/"
X Link 2025-02-19T16:31Z [---] followers, [---] engagements
"$SPRY made a bullish move after reporting its earnings. The company narrowly beat Neffy sales forecasts for [----] though the majority of its revenue came from partnerships and supply agreements. https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/ https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/"
X Link 2025-03-20T16:23Z [---] followers, [--] engagements
"$EWTX and $CYTK diverged Wednesday after Edgewise put out promising results for its HCM drug but noted four patients experienced atrial fibrillation. Analysts were mostly unconcerned noting afib tends to occur in the HCM population"
X Link 2025-04-02T16:00Z [---] followers, [---] engagements
"It's important to note Cytokinetics is several years ahead of Edgewise with its PDUFA for aficamten in obstructive HCM scheduled for September. Read on here: https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/ https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/"
X Link 2025-04-02T16:00Z [---] followers, [---] engagements
"$CGON rocketed as much as 44% on promising results for its $JNJ-rivaling bladder cancer drug. https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/ https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/"
X Link 2025-04-28T15:40Z [---] followers, [---] engagements
"I'm playing catch-up after being out of the office for a few days. $HIMS had a mixed Q1 report and shares fell on its light Q2 outlook. $VRTX is also under pressure on a series of setbacks including a pause for its mRNA-based CF drug. $NBIX though saw momentum for Crenessity"
X Link 2025-05-06T16:39Z [---] followers, [---] engagements
"Read more from Neurocrine's report here: Vertex raised the low side of its outlook despite missing Q1 sales calls: Hims is planning to sign more partnerships after the $NVO news last week: https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/ https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/neurocrine-biosciences-stock-neurocrine-biosciences-earnings-q1-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/"
X Link 2025-05-06T16:41Z [---] followers, [---] engagements
"Dollar stock $VIGL skyrocketed after $SNY agreed to buy it for $470 million. The deal includes a CVR that brings the total value up to $600 million. https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/ https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/"
X Link 2025-05-22T16:06Z [---] followers, [---] engagements
"$APGE reversed steep premarket gains despite promising results for its eczema drug a potential twice-yearly shot. The results are comparable to $SNY and $REGN's Dupixent and $LLY's Ebglyss. https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/ https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/"
X Link 2025-07-07T16:58Z [---] followers, [---] engagements
"$WST surged retaking its 200-day line after beating sales and earnings expectations. The supplier of injectable drug delivery systems also raised its outlook for the year. https://www.investors.com/news/technology/west-pharmaceutical-stock-west-pharmaceutical-earnings-q2-2025/ https://www.investors.com/news/technology/west-pharmaceutical-stock-west-pharmaceutical-earnings-q2-2025/"
X Link 2025-07-24T16:51Z [---] followers, [---] engagements
"I'm back from a weeklong staycation to celebrate my twins' fifth birthday. The morning kicked off with $IDXX shooting higher on its earnings report. The company is tied to the animal-health space. https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/ https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/"
X Link 2025-08-04T15:38Z [---] followers, [---] engagements
"A year after spiking on progression-free survival results for its bispecific antibody targeting PD-1 and VEGF $SMMT crashed. Overall survival data which the Street was closely watching didn't meet statistical significance. $BNTX also fell. https://www.investors.com/news/technology/summit-therapeutics-stock-pd-1-vegf-lung-cancer-treatment/ https://www.investors.com/news/technology/summit-therapeutics-stock-pd-1-vegf-lung-cancer-treatment/"
X Link 2025-09-08T20:12Z [---] followers, [---] engagements
"Why one analyst says $NVS' $1.4 billion takeover of $TRML just "makes sense." $NVO https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/ https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/"
X Link 2025-09-09T14:35Z [---] followers, [---] engagements
"$MBX doubled and then some after putting out promising results for its thyroid disease drug. $ASND is down somewhat. But analysts note it has the first-mover advantage in this space. https://www.investors.com/news/technology/mbx-biosciences-mbx-stock-parathyoid-treatment/ https://www.investors.com/news/technology/mbx-biosciences-mbx-stock-parathyoid-treatment/"
X Link 2025-09-22T17:09Z [---] followers, [---] engagements
"In earnings news $TGTX beat expectations and raised its outlook but fell on a caveat that undercut its massive profit beat. $IDXX also topped forecasts and shares broke out to a record high. https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/ https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/"
X Link 2025-11-03T18:20Z [---] followers, [---] engagements
"It was a busy day in the oncology space. $NUVL surged by double digits on positive results in ALK-mutated lung cancer while $JAZZ and $ZYME rocketed on what one analyst called "unprecedented" results in gastric cancer. https://www.investors.com/news/technology/nuvalent-stock-nsclc-alk-mutation-treatment/ https://www.investors.com/news/technology/jazz-pharmaceuticals-zymeworks-gastric-cancer-ziihera/ https://www.investors.com/news/technology/nuvalent-stock-nsclc-alk-mutation-treatment/ https://www.investors.com/news/technology/jazz-pharmaceuticals-zymeworks-gastric-cancer-ziihera/"
X Link 2025-11-17T22:41Z [---] followers, [---] engagements
"In more oncology news $OLMA is up by triple digits after $RHHBY (up by double digits) reported promising results for an oral SERD in patients with breast cancer. Here's why Olema soared on Roche's results: https://www.investors.com/news/technology/biotech-stock-olema-pharmaceuticals-roche-oral-serd-breast-cancer-treatment/ https://www.investors.com/news/technology/biotech-stock-olema-pharmaceuticals-roche-oral-serd-breast-cancer-treatment/"
X Link 2025-11-18T18:26Z [---] followers, [---] engagements
"$JANX is down almost 50% on mixed results for its prostate cancer treatment. But analysts are upbeat saying its drug could eventually be a blockbuster. https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/ https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/"
X Link 2025-12-02T17:17Z [---] followers, [---] engagements
"$PHVS and $KALV surged after Pharvaris reported promising results for its treatment for HAE attacks. https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/ https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/"
X Link 2025-12-03T19:15Z [---] followers, [---] engagements
"$ARGX toppled after stopping a study of Vyvgart in patients with thyroid eye disease. Analyst say the decision isn't a big hit for Vyvgart but could bolster $VRDN. https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/ https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/"
X Link 2025-12-15T17:23Z [---] followers, [---] engagements
"The White House is about to make a major announcement about drug prices. While the camera was briefly turned on a poster board showed $GSK $RHHBY and $SNY's names"
X Link 2025-12-19T19:05Z [---] followers, [---] engagements
"@thehill Trump says there are nine pharmaceutical companies. "Celebrities in their own right." They agreed to offer many of their flagship drugs at heavily discounted MFN prices. "Whatever the drug sells for in the world whatever the lowest number is. we will match that price.""
X Link 2025-12-19T19:25Z [---] followers, [---] engagements
"$ZBIO quadrupled in [----]. But shares hit the skids on Monday despite a technical Phase [--] win. Here's what happened: https://www.investors.com/news/technology/zenas-biopharma-stock-igg4-related-disease-treatment/ https://www.investors.com/news/technology/zenas-biopharma-stock-igg4-related-disease-treatment/"
X Link 2026-01-06T01:18Z [---] followers, [---] engagements
"$ALMS more than doubled today on test results for its plaque psoriasis drug a potential rival to oral meds from $JNJ $PTGX and $TAK. https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/ https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/"
X Link 2026-01-06T16:28Z [---] followers, [---] engagements
"$BEAM surged after the company said it could have a path to accelerated approval for its AATD treatment. https://www.investors.com/news/technology/beam-stock-beam-therapeutics-jpm-updates-gene-editing-drugs/ https://www.investors.com/news/technology/beam-stock-beam-therapeutics-jpm-updates-gene-editing-drugs/"
X Link 2026-01-12T18:34Z [---] followers, [---] engagements
"#JPM2026 so far has been marked by a slew of preannouncements for the fourth quarter. Here are the winners and losers from day one: $ANY $SRPT $IRTC $DAWN $ANIP https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/ https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/"
X Link 2026-01-12T18:36Z [---] followers, [----] engagements
"$ISRG is under pressure after issuing a lackluster view for [----] procedure growth. $GKOS also took a hit on its guidance. https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/ https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/"
X Link 2026-01-14T16:47Z [---] followers, [---] engagements
"$RAPT soared after $GSK agreed to buy it for $2.2 billion. Rapt is working on a preventative treatment for food allergies. https://www.investors.com/news/technology/rapt-stock-gsk-buyout/ https://www.investors.com/news/technology/rapt-stock-gsk-buyout/"
X Link 2026-01-20T18:25Z [---] followers, [---] engagements
"$CORT surged after its ovarian cancer regimen met the overall survival bar in a late-stage study. https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/ https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/"
X Link 2026-01-22T17:28Z [---] followers, [---] engagements
"$ISRG disappointed investors earlier this month with its 13%-15% guidance for [----] procedure growth for da Vinci. But an analyst says it's not all gloom for the robotic surgery stock. https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/"
X Link 2026-01-23T17:36Z [---] followers, [---] engagements
"$NVO's oral Wegovy clocked in at [-----] prescriptions (likely not including NovoCare) in its second week. That's far and away north of the [----] from $LLY's Zepbound in its second week of launch. https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/"
X Link 2026-01-23T17:37Z [---] followers, [----] engagements
"In other earnings news $SNY beat earnings forecasts and Dupixent sales came in ahead though total sales were light. Its key partner $REGN reports tomorrow morning. https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/ https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/"
X Link 2026-01-29T21:24Z [---] followers, [---] engagements
"$NVO unexpectedly released its fourth-quarter report and [----] outlook a day early. The company calls for sales and operating profit to decline this year"
X Link 2026-02-03T17:30Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing